Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the ...

Please provide your email address to receive an email when new articles are posted on . Metformin did not improve 6-minute walk distance in patients with peripheral artery disease but no diabetes.

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Diabetes affects over half a billion people globally. Along with direct consequences to those with the disease, it also contributes to and predisposes affected individuals to a host of other ...

Research led by CU cardiologist Marc Bonaca, MD, is a step forward in improving treatment options for patients with peripheral artery disease and type 2 diabetes, revealing that semaglutide improved ...

Please provide your email address to receive an email when new articles are posted on . Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. An ...

Peripheral Vascular Disease (PVD) often goes unnoticed — but your legs may be showing earlywarning signs long before serious ...

Diabetes independently predicts major adverse cardiovascular events in patients with psoriasis and coronary artery disease, especially in males and those without chronic kidney disease. Patients with ...

FUNDING ITS DEVELOPMENT. IN TONIGHT’S WOMAN’S DOCTOR, BLACK WOMEN ARE MORE LIKELY TO DEVELOP PERIPHERAL ARTERY DISEASE, OTHERWISE KNOWN AS PAD. THESE CASES TEND TO START IN YOUNGER WOMEN, IN BLACK ...

Imagine putting your socks on one morning and noticing your big toe, which has been painful for a few weeks, has started turning black. A trip to your doctor ends in being referred urgently to a ...